# Evolution Therapy

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/evolution-therapy

- Industry: Biotechnology
- Headquarters: Beijing, China
- Latest round: Angel (May 9, 2026)
- Investors on record: 2

## About

Based in Beijing, China and founded in 2023, Micro Evolution (Beijing) Medical Technology Co., Ltd., dba Evolution Therapy, operates as a biotechnology company that focuses on providing cross-species oncology gene therapy services. Peng Du, the founder of the company, graduated from Harvard Medical School and served as a researcher and associate professor in the School of Life Sciences at Peking University. He was awarded the National Outstanding Youth Science Foundation. The company has completed the industrialization landing project in Zibo. In May 2026, Evolution Therapy closed Angel funding from Chengdu Science and Technology Venture Capital Group.

Evolution Therapy's main business is the research and development of a gene therapy platform based on plant immune protein-mediated gene therapy. It developed the plant RDR1 protein-mediated miRNA repair therapy, which is able to become a broad-spectrum antitumor method for multiple cancer indications. The protein-mediated miRNA repair therapy can be used in the treatment of relapsed and refractory cancers.

The company generates revenue by providing plant RDR1 protein-mediated miRNA repair therapy.

## Funding rounds

- Angel, May 9, 2026 — Chengdu Science and Technology Venture Capital Group
- Angel, Jun 6, 2024 — Galileo Ventures

## Investors

- Galileo Ventures — Angel
- Chengdu Science and Technology Venture Capital Group (https://capitalatlas.ai/funds/chengdu-science-and-technology-venture-capital-group) — Angel